Indian Cabinet Ministers In Stalemate Over New Pharma Policy
This article was originally published in PharmAsia News
Executive Summary
Three Indian Cabinet ministers responsible for reaching a compromise on the country's drug policy are stalemated. The health and chemicals ministries, led by the agriculture minister, were assigned to sort out the policy. The health ministry wants quality control and drug supplies to be excluded from the policy. The chemicals ministry, which has administrative authority over pharmas, drafted the policy, but quality regulation and marketing approvals are under the purview of the health ministry. The agriculture minister told both sides to work out their differences. (Click here for more
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.